Skip to main content

Table 1 Patient characteristics

From: Prognostic value of resting coronary sinus flow determined by phase-contrast cine cardiovascular magnetic resonance in patients with known or suspected coronary artery disease

 

All patients N = 1212

Patients with known CAD N = 693

Patients with suspected CAD N = 519

*P-value

Clinical variables

 Age, years

69 ± 10

69 ± 10

68 ± 11

0.37

 Male

921 (76%)

554 (80%)

367 (71%)

< 0.005

 BMI, kg/m2

24 ± 3

24 ± 3

24 ± 4

0.49

 Hypertension

823 (68%)

483 (70%)

340 (66%)

0.13

 Dyslipidemia

821 (68%)

488 (70%)

333 (64%)

0.021

 Diabetes mellitus

366 (30%)

229 (33%)

137 (26%)

0.012

 Current smoking

79 (7%)

55 (8%)

24 (5%)

0.021

Blood test

 HbA1c, %

6.0 ± 0.8

6.1 ± 0.9

5.9 ± 0.7

0.005

 LDL cholesterol

99 ± 28

94 ± 27

107 ± 30

< 0.001

 eGFR

66 ± 16

67 ± 16

66 ± 15

0.42

CMR variables

 LVEDV, mL

131 ± 46

128 ± 42

134 ± 51

0.053

 LVESV, mL

57 ± 37

55 ± 33

59 ± 42

0.24

 LV mass, g

95 ± 34

92 ± 36

99 ± 31

< 0.001

 LVEF, %

60 ± 12

60 ± 12

59 ± 12

0.84

 Presence of LGE

591 (49%)

439 (63%)

152 (29%)

< 0.001

 LGE, %

7.9 ± 9.0

9.6 ± 9.6

5.9 ± 7.7

< 0.001

 Presence of ischemia

516 (43%)

195 (28%)

321 (62%)

0.002

 > 10% ischemia

258 (21%)

175 (25%)

83 (16%)

< 0.001

  1. Data are expressed as mean ± SD or number (%)
  2. *P-value represents significance of difference between patients with known CAD and suspected CAD
  3. BMI body mass index, CAD coronary artery disease, CFR coronary flow reserve, CMR cardiac magnetic resonance, eGFR estimated glomerular filtration rate, LDL low-density lipoprotein, LGE late gadolinium enhancement, LV left ventricular, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, MACE major adverse cardiac events